In patients with non-alcoholic steatohepatitis (NASH)-derived hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC), increased expression of LTβR correlated with disease progression and a worsened prognosis [19–21]. This evidence concerns the gene LTBR and metabolic dysfunction-associated steatohepatitis.